Esperion Therapeutics to Present at BioCentury Future Leaders in the Biotech Industry Conference

Presentation and Webcast Held Friday, March 28 at 2:30 p.m. Eastern Time

21st Annual BioCentury Future Leaders

PLYMOUTH, Mich.--()--Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Tim M. Mayleben, Esperion’s president and chief executive officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry conference in New York City. The presentation and webcast will take place on Friday, March 28, 2014 at 2:30 p.m. Eastern Time.

A live, listen-only webcast of the presentation can be accessed on the investor relations section of the Esperion website at investor.esperion.com/events. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the Company's website for 90 days following the event.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with the currently-available LDL-cholesterol lowering therapies. ETC-1002 is being developed primarily for patients intolerant of statins with elevated levels of LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are currently underway and build upon a successful and comprehensive Phase 1 and Phase 2 program. For more information, please visit www.esperion.com.

Contacts

Media Contact:
W2O Group
Elliot Fox, 212.257.6724
efox@w2ogroup.com

Sharing

Contacts

Media Contact:
W2O Group
Elliot Fox, 212.257.6724
efox@w2ogroup.com